Bank Of New York Mellon Corp Avidity Biosciences, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$15.35 - $25.65 $3.56 Million - $5.94 Million	231,648 New	231,648 $3.56 Billion
Q4 2022 Feb 14, 2023	BUY	$10.06 - $22.66 $1.97 Million - $4.44 Million	196,093 New	196,093 $4.35 Million
Q3 2022 Nov 14, 2022	BUY	$15.46 - $23.43 $294,451 - $446,247	19,046 Added 12.15%	175,800 $2.87 Million
Q2 2022 Aug 15, 2022	BUY	$11.18 - $20.5 $225,086 - $412,726	20,133 Added 14.74%	156,754 $2.28 Million
Q1 2022 May 11, 2022	BUY	$14.2 - $23.78 $10,209 - $17,097	719 Added 0.53%	136,621 $2.52 Million
Q4 2021 Feb 11, 2022	BUY	$20.4 - $28.66 $314,343 - $441,621	15,409 Added 12.79%	135,902 $3.23 Million
Q3 2021 Nov 12, 2021	BUY	$18.16 - $25.21 $473,558 - $657,401	26,077 Added 27.62%	120,493 $2.97 Million
Q2 2021 Aug 11, 2021	BUY	$19.62 - $29.26 $195,513 - $291,575	9,965 Added 11.8%	94,416 $2.33 Million
Q1 2021 May 13, 2021	BUY	$20.28 - $28.15 $429,469 - $596,132	21,177 Added 33.47%	84,451 $1.84 Million
Q4 2020 Feb 09, 2021	BUY	$24.73 - $35.12 $411,482 - $584,361	16,639 Added 35.68%	63,274 $1.61 Million
Q3 2020 Nov 12, 2020	BUY	$23.35 - $35.94 $1.09 Million - $1.68 Million	46,635 New	46,635 $1.31 Million

252

110M

197K

184K

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $1.72B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.